Formosa Pharmaceuticals has announced an exclusive licensing agreement with Tabuk Pharmaceuticals, granting the latter exclusive rights to commercialise the clobetasol propionate ophthalmic suspension, 0.05% (APP13007) to treat inflammation and pain after ocular surgery.
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO...
US FDA approves Eyenovia`s eye drug, Formosa Pharma says
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália
Zhejiang Yongtai`s Generic Clobetasol Propionate Receives Approval in the U.S.
Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of February 1, 2023
Salvat, the international laboratory that has developed and owns Cristalmina, Gama Relive, Tebarat and Cetraxal products, has submitted the NDA documentation for a new drug application to the U.S. Food and Drug Administration (FDA) for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.